US$ 26.69
glp-1 obesity drug updates today The revolution: What UAB researchers are discovering about how these drugs work Poll: 1 in 8 Adults
Description
In the longer-term trials that reported individual adverse event categories associated with discontinuation of drug treatment, nausea was shown to be the leading cause of discontinuation, followed by vomiting and diarrhea, with much lower risks associated with constipation, abdominal discomfort, or pain (Table 3)

Pasternak, B

On the other hand, GLP-1 RA can reduce epicardial fat and semaglutide 2.4 mg have shown to improve physical function and symptoms in people with HFpEF [93]

Losing 5 to 10 percent of body weight, even temporarily, carries meaningful health benefits

Medical News Today
doi: 10.1016/S2213-8587(23)00356-X [DOI] [PubMed] [Google Scholar] 81
